<?xml version="1.0" encoding="UTF-8"?>
<p>The coronavirus disease 2019 (COVID‐19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) that was first identified in December 2019 in Wuhan, China, and is currently circulating throughout the world.
 <xref rid="iub2356-bib-0001" ref-type="ref">
  <sup>1</sup>
 </xref> By July 5, 2020, more than 11,125,245 million cases have been diagnosed in 216 countries, and more than 528,204 deaths have been reported.
 <xref rid="iub2356-bib-0002" ref-type="ref">
  <sup>2</sup>
 </xref> The ongoing COVID‐19 pandemic highlights the critical need for rapid development of vaccines and antiviral treatments to reduce the number of hospitalizations and deaths caused by this new dangerous coronavirus.
 <xref rid="iub2356-bib-0003" ref-type="ref">
  <sup>3</sup>
 </xref> Co‐infections and superinfections are common in respiratory viral infections.
 <xref rid="iub2356-bib-0004" ref-type="ref">
  <sup>4</sup>
 </xref>, 
 <xref rid="iub2356-bib-0005" ref-type="ref">
  <sup>5</sup>
 </xref> According to the laboratory, clinical, and epidemiological studies, secondary or bacterial co‐infections with other viruses can significantly increase the mortality rate in patients infected with viral infections.
 <xref rid="iub2356-bib-0006" ref-type="ref">
  <sup>6</sup>
 </xref>, 
 <xref rid="iub2356-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref> It has previously documented that the mortality rate of viral infections can be influenced by different factors, such as bacterial co‐infection.
 <xref rid="iub2356-bib-0008" ref-type="ref">
  <sup>8</sup>
 </xref>, 
 <xref rid="iub2356-bib-0009" ref-type="ref">
  <sup>9</sup>
 </xref>, 
 <xref rid="iub2356-bib-0010" ref-type="ref">
  <sup>10</sup>
 </xref> For instance, influenza‐related bacterial infections contribute to severe illness and mortality during the epidemic and seasonal influenza outbreaks.
 <xref rid="iub2356-bib-0011" ref-type="ref">
  <sup>11</sup>
 </xref> Some influenza‐related bacterial species include 
 <italic>Streptococcus pyogenes</italic>, 
 <italic>Neisseria meningitidis</italic>, 
 <italic>Moraxella catarrhalis</italic>, 
 <italic>Streptococcus pneumoniae</italic>, 
 <italic>Haemophilus influenzae</italic>, and 
 <italic>Staphylococcus aureus</italic>.
 <xref rid="iub2356-bib-0011" ref-type="ref">
  <sup>11</sup>
 </xref>, 
 <xref rid="iub2356-bib-0012" ref-type="ref">
  <sup>12</sup>
 </xref>, 
 <xref rid="iub2356-bib-0013" ref-type="ref">
  <sup>13</sup>
 </xref>, 
 <xref rid="iub2356-bib-0014" ref-type="ref">
  <sup>14</sup>
 </xref>, 
 <xref rid="iub2356-bib-0015" ref-type="ref">
  <sup>15</sup>
 </xref>, 
 <xref rid="iub2356-bib-0016" ref-type="ref">
  <sup>16</sup>
 </xref>, 
 <xref rid="iub2356-bib-0017" ref-type="ref">
  <sup>17</sup>
 </xref>, 
 <xref rid="iub2356-bib-0018" ref-type="ref">
  <sup>18</sup>
 </xref> The mechanisms of severe complications caused by influenza‐bacterial co‐infections mainly include a lack of effective immune response as well as pathogenic synergy.
 <xref rid="iub2356-bib-0005" ref-type="ref">
  <sup>5</sup>
 </xref> Although multiple microbial agents can cause acute lower respiratory tract infections, in most cases, the disease is caused by viruses and bacteria at the same time.
 <xref rid="iub2356-bib-0019" ref-type="ref">
  <sup>19</sup>
 </xref> Secondary and bacterial co‐infections with pandemics and viral epidemics have irreversible consequences, especially in high‐risk groups, including those with immunodeficiency or immunosuppression.
 <xref rid="iub2356-bib-0020" ref-type="ref">
  <sup>20</sup>
 </xref>
</p>
